Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02924194
Recruitment Status : Recruiting
First Posted : October 5, 2016
Last Update Posted : October 5, 2016
Sponsor:
Collaborator:
Barrow Neurological Foundation
Information provided by (Responsible Party):
St. Joseph's Hospital and Medical Center, Phoenix

Brief Summary:
The purpose of this study is to evaluate the safety and effectiveness of deep brain stimulation of the nucleus basalis of Meynert (also called the "nbM") at improving memory in Parkinson's disease patients with mild cognitive impairments and memory difficulties. Patients with Parkinson's disease (PD) that are eligible for Deep Brain Stimulation (DBS) therapy for improvement of their motor symptoms and with evidence of mild cognitive impairments and memory difficulties will be enrolled.

Condition or disease Intervention/treatment Phase
Parkinson's Disease Mild Cognitive Impairment Device: stimulation ON Device: stimulation OFF Not Applicable

Detailed Description:
This is a prospective, double-blind (patient and neuropsychologist), randomized, cross-over study to evaluate the safety of deep brain stimulation of the nucleus basalis of Meynert (nbM) in Parkinson's disease (PD) patients with mild cognitive impairment (PD-MCI) who are undergoing globus pallidus internus (GPi) stimulation for their motor symptoms. Six patients with PD who are eligible for GPi DBS for improvement of their motor symptoms and who have a clinical diagnosis of PD-MCI (amnestic, single or multiple domain) per Movement Disorder Society (MDS) criteria will be enrolled and implanted with bilateral electrodes in in the nbM in addition to the globus pallidus internus (GPi). Conventional stereotactic implantation of the electrodes will be guided by intraoperative computerized tomography (CT) and magnetic resonance tomography (MRT).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 6 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Deep Brain Stimulation (DBS) of the Nucleus Basalis of Meynert (nbM) to Treat Parkinson's Patients With Mild Cognitive Impairment, Amnestic Subtype
Study Start Date : September 2016
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : April 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: nbM stimulation ON for 3 months (GPi also on)
Subjects will undergo activation of GPi and nbM electrodes The GPi's will be stimulated to achieve improvement in motor function. There is a double blind evaluation of DBS-nbM stimulation. Subjects will be those with nbM stimulation ON for a period of 3 months (GPi also on). No usual treatment is withheld. PD drug doses will be stable unless disabling dyskinesias warrants a reduction of medication. After initial 3 months period of stimulation subject will undergo a repeat of neuropsychological testing and Motor Unified Parkinson's Disease Rating Scale (UPDRS) rating prior to switching group assignment (cross-over). There will be a 2 day wash-out period of nbM stimulation for all subjects (both the On and Off groups) in order to minimize subject bias. Then, the subjects will undergo additional brief neuropsychological testing to asses for carry over effects. The subjects will then be switched to the alternate nbM stimulation group (cross-over) from their previous 3 month period.
Device: stimulation ON
The system used in the study includes the Model 37601 Activa PC stimulator, Model 3387 Lead and Model 37085 Extension, all manufactured and commercially available by Medtronic, Inc. Collectively, these devices will be referred to as "the DBS System". The DBS System is commercially available in the United States and was approved by FDA on July 31, 1997 under PMA P960009. It is indicated for deep brain stimulation for the treatment of symptoms of Parkinson's disease and essential tremor.

Experimental: nbM stimulation OFF for 3 months (GPi is on)
Subjects will undergo activation of GPi and nbM electrodes The GPi's will be stimulated to achieve improvement in motor function. There is a double blind evaluation of DBS-nbM stimulation. Subjects will be those with nbM stimulation OFF for a period of 3 months (GPi is on). No usual treatment is withheld. PD drug doses will be stable during blinded parts of the assessment unless disabling dyskinesias warrants a reduction of medication. After initial 3 months period of stimulation subject will undergo a repeat of neuropsychological testing and Motor UPDRS rating prior to switching group assignment (cross-over). There will be a 2 day wash-out period of nbM stimulation for all subjects (both the On and Off groups) in order to minimize subject bias. Then, the subjects will undergo additional brief neuropsychological testing to asses for carry over effects. The subjects will then be switched to the alternate nbM stimulation group (cross-over) from their previous 3 month period.
Device: stimulation OFF
The system used in the study includes the Model 37601 Activa PC stimulator, Model 3387 Lead and Model 37085 Extension, all manufactured and commercially available by Medtronic, Inc. Collectively, these devices will be referred to as "the DBS System". The DBS System is commercially available in the United States and was approved by FDA on July 31, 1997 under PMA P960009. It is indicated for deep brain stimulation for the treatment of symptoms of Parkinson's disease and essential tremor.




Primary Outcome Measures :
  1. Evaluate safety of DBS-nbM [ Time Frame: Month 36 ]
    Evaluate safety through collection of adverse events at weeks 4, 16, 28, 52 and months 24 and 36.


Secondary Outcome Measures :
  1. Stability or improvement of cognitive symptoms [ Time Frame: Month 36 ]
    Administration of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) administered at Week 52 and Months 24 and 36. A clinically meaningful change is indicated by a 4 point change in ADAS-Cog.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Informed consent signed by the subject.
  • Parkinson's disease per UK Parkinson's Disease Society Brain Bank (Queens Square) criteria
  • Diagnosis of PD-MCI, amnestic subtype per MDS criteria (Level II assessment)
  • DBS candidate for GPi targeting per the consensus committee
  • 50 - 75 years of age
  • Primary English speaking
  • Minimum of 10 years of education
  • Motorically and cognitively capable of completing evaluations and consent
  • Medically cleared for surgery and anesthesia
  • Subject must be on stable doses of any medication used to treat PD or cognition for 3 months prior to study entry
  • Female subjects with child-bearing potential have a negative serum pregnancy test prior to DBS surgery -

Exclusion Criteria:

  • Dementia per DSM-V criteria
  • Condition precluding MRI
  • History of supraspinal CNS disease other than PD
  • Medical condition or required medication compromising cognition
  • Alcohol use of more than 4 drinks per day
  • Currently uncontrolled moderate-severe depression (BDI>20)
  • History of suicide attempt in the year preceding study screening
  • History of schizophrenia, delusions, or currently uncontrolled visual hallucinations
  • Use of cholinesterase inhibitor
  • Subjects who require rTMS, ECT, diathermy, or repeat MRI procedures to treat a medical condition.
  • Subjects with a history of seizure disorder
  • Subjects who have made a suicide attempt within the prior year,
  • Subjects with any medical contraindications to undergoing DBS surgery (eg, infection, coagulopathy, or significant cardiac or other medical risk factors for surgery)
  • Subjects with an implanted stimulator such as a cardiac pacemaker, defibrillator, neurostimulator and cochlear implant
  • Subjects who are pregnant or nursing.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02924194


Contacts
Layout table for location contacts
Contact: Meg Lambert, RN, BSN 602-406-3755 margaret.lambert@dignityhealth.org

Locations
Layout table for location information
United States, Arizona
St. Joseph's Hospital and Medical Center Recruiting
Phoenix, Arizona, United States, 85205-6118
Contact: Meg Lambert, RN, BSN    602-406-3755    margaret.lambert@dignityhealth.org   
Principal Investigator: Francisco A Ponce, MD         
Sponsors and Collaborators
St. Joseph's Hospital and Medical Center, Phoenix
Barrow Neurological Foundation
Investigators
Layout table for investigator information
Principal Investigator: Francisco A Ponce, MD Barrow Brain and Spine

Layout table for additonal information
Responsible Party: St. Joseph's Hospital and Medical Center, Phoenix
ClinicalTrials.gov Identifier: NCT02924194     History of Changes
Other Study ID Numbers: PHX-16-0141-30-06
First Posted: October 5, 2016    Key Record Dates
Last Update Posted: October 5, 2016
Last Verified: October 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Cognition Disorders
Neurocognitive Disorders
Mental Disorders
Cognitive Dysfunction